ASX Linkedin Twitter               

 

Clinical Trials – Phase 1 in NSCLC

Status – in Start-up

A site-sponsored Phase Ib open-label trial to investigate the use of intravenous CAVATAK® in combination with pembrolizumab (KEYTRUDA™) for the treatment of patients with advanced Non Small Cell Lung Cancer (NSCLC) is in start-up at the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia.

The trial is designed to assess the safety and tolerability of the CAVATAK/KEYTRUDA combination therapy and will be conducted in two parts: the first part will assess the safety of three ascending dose levels of intravenously-delivered CAVATAK in combination with a fixed dose of pembrolizumab. Once a safe dose of CAVATAK has been determined, the second part will enroll additional subjects to further evaluate safety and assess efficacy by overall response and changes in the tumor microenvironment. The study may enrol up to 30 patients.

For information about this trial, please visit the Clinical Trial website at clinicaltrials.gov, Identifier NCT02824965.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).